Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL

Autor: Mars B. van't Veer, Eva Kimby, Jesper Jurlander, Geir E. Tjønnfjord, Martine C. J. Abrahamse-Testroote, Jeanette K. Doorduijn, Tomas Kozak, Maija Itälä Remes, Ka Lung Wu, Wendimagegn Ghidey Alemayehu, Christian H. Geisler, Marinus H. J. van Oers, Aaron Polliack, Shulamiet Wittebol, Jan Walewski

Publikováno v: Blood, 123(21), 3255-3262. American Society of Hematology

The randomized Haemato Oncology Foundation for Adults in The Netherlands 68 phase 3 trial compared front-line chemotherapy with chemotherapy plus the CD52 monoclonal antibody alemtuzumab for high-risk chronic lymphocytic leukemia, defined as at least

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb2e0c4b03a79357e962838dcc0036bf
https://pure.eur.nl/en/publications/8ab18375-b974-4820-a739-8e123aa1641b

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease

Autor: Emmanuel Gyan, J.H. Meerwaldt, Chantal Rieux, Jean Gabarre, Eric Van Den Neste, Pieternella J. Lugtenburg, Pierre Lederlin, Jan Walewski, Christophe Fermé, Pauline Brice, Houchingue Eghbali, Philip Poortmans, Jacques Bosq, Michel Henry-Amar, Geert Jan Creemers, José Thomas, Christian Carrie, Patrice Carde, Oumedaly Reman, Marine Diviné, Johanna Kluin-Nelemans, Michel Blanc, Jérôme Jaubert, Gilles Salles, Anton Hagenbeek, Theodore Girinsky, Mars B. van't Veer, Françoise Berger, Joke W. Baars, Umberto Tirelli, B. Vie, John M. M. Raemaekers, Mathieu Monconduit, Fernando Viseu, Evert M. Noordijk

Publikováno v: The New England Journal of Medicine, 357, 1916-27
The New England Journal of Medicine, 357, 19, pp. 1916-27
New England Journal of Medicine, 357(19), 1916-1927. Massachussetts Medical Society
New England journal of medicine, 357(19), 1916-1927. Massachussetts Medical Society
New England Journal of Medicine, 357(19), 1916-1927. MASSACHUSETTS MEDICAL SOC

Item does not contain fulltext BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cf0f86aed2b9569e0fd3ead1f269ddd
https://doi.org/10.1056/nejmoa064601

Optimal treatment of premature ovarian failure after treatment for Hodgkin's lymphoma is often withheld

Autor: Mars B. van't Veer, Theo Stijnen, Anca C. Ansink, Jiska J. Schaap, Curt W. Burger, Sylvia I. Verschuuren

Publikováno v: Acta Obstetricia et Gynecologica Scandinavica, 85(8), 997-1002. Wiley-Blackwell

Background. The purpose of this study is to determine: 1. the effect of treatment for Hodgkin's lymphoma on ovarian function, and 2. the interventions to relieve postmenopausal symptoms. Methods. Seventy-seven consecutive patients treated between 198

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57fde812672a39c023754b3fa53060fd
https://pure.eur.nl/en/publications/ce5d747c-a4ff-46f4-9c94-4669abe0f89d

High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma

Autor: Martine Van Glabbeke, Pierre Soubeyran, Martin J. van den Bent, José Thomas, H. Haaxma-Reiche, Cynthia Rozewicz, Mars B. van't Veer, I. Teodorovic, Philip Poortmans, Hanneke C. Kluin-Nelemans, Mads Hansen, Gustaaf W. van Imhoff, Martin J B Taphoorn, Martin Fickers

Publikováno v: Journal of Clinical Oncology, 21(24), 4483-4488. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 21(24), 4483-4488. American Society of Clinical Oncology

Purpose: To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, carmustine, and methylprednisolone (MBVP) chemotherapy combined with radiotherapy (RT) for patients with non–AIDS-related primary CNS lymphoma (PCNSL)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e310e1271cfc8ef80c415c0c2c871b07
https://doi.org/10.1200/JCO.2003.03.108

Long-term cause-specific mortality of patients treated for Hodgkin's disease

Autor: Willem J. Klokman, Harry Bartelink, Berthe M.P. Aleman, Alexandra W. van den Belt-Dusebout, Mars B. van't Veer, Flora E. van Leeuwen

Publikováno v: Journal of Clinical Oncology, 21(18), 3431-3439. American Society of Clinical Oncology

Purpose: To assess long-term cause-specific mortality of young Hodgkin’s disease (HD) patients. Patients and Methods: The study population consisted of 1,261 patients treated for HD before age 41 between 1965 and 1987. Follow-up was complete until

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a85ebafabee95f16745a4b0f442d1a1
https://doi.org/10.1200/JCO.2003.07.131